Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem

Clinical Therapeutics

Volumn 22, Issue 12, 2000, Pages 1443-1461

  Drover, David ^a   Lemmens, Harry ^a   Naidu, Sujata ^a   Cevallos, William ^b   Darwish, Mona ^b   Stanski, Donald ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

Pharmacodynamics; Population pharmacokinetics; Zaleplon; Zolpidem

Indexed keywords

HYPNOTIC AGENT; PLACEBO; PYRAZOLOPYRIMIDINE DERIVATIVE; ZALEPLON; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY; MOOD; MOTOR PERFORMANCE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RECALL; SEDATION; SIDE EFFECT;

EID: 0034534720     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83043-X     Document Type: Article

References (20)

1. Pharmacology of CL 284,846, a non-benzodiazepine sedative with reduced amnestic liability
2. CL 284,846, a novel sedative-hypnotic: Evaluation of its metabolites for pharmacological activity in vitro and in vivo
3. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo
4. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
5. The effects of single doses of CL284,846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers
6. Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide
7. Absorption rate, blood concentrations, and early response to oral chlordiazepoxide
8. Memory I: Tests: Neuropsychological Assessment 3rd ed
9. A placebo-controlled evaluation of single, escalating doses of CL 284,846, a non-benzodiazepine hypnotic
10. Measuring the predictive performance of computer-controlled infusion pumps
11. max model for use with truncated PK/PD data
12. max-model without attaining maximal effects
13. Zaleplon pharmacokinetics and absolute bioavailability
14. EEG profile of intravenous zolpidem in healthy volunteers
15. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I)
16. A Phase III, 28 day, multicenter, randomized, double-blind comparator- and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10, and 20 mg of zaleplon, compared with 10 mg of zolpidem or placebo, in adult outpatients with insonmia
17. Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance
18. max model with truncated data typical of clinical studies?